Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice.
Identifieur interne : 002891 ( PubMed/Curation ); précédent : 002890; suivant : 002892Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice.
Auteurs : Huali Jin [République populaire de Chine] ; Chong Xiao ; Ze Chen ; Youmin Kang ; Yijie Ma ; Kaichun Zhu ; Qifa Xie ; Yixian Tu ; Yang Yu ; Bin WangSource :
- Biochemical and biophysical research communications [ 0006-291X ] ; 2005.
Descripteurs français
- KwdFr :
- Activation des lymphocytes (), Activation des lymphocytes (génétique), Activation des lymphocytes (immunologie), Adjuvants immunologiques (métabolisme), Animaux, Cytokines (immunologie), Femelle, Lymphocytes auxiliaires Th1 (), Lymphocytes auxiliaires Th1 (immunologie), Lévamisole (administration et posologie), Protéines nucléocapside (génétique), Protéines nucléocapside (immunologie), Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère (), Syndrome respiratoire aigu sévère (génétique), Syndrome respiratoire aigu sévère (immunologie), Thérapie génétique (), Traitement médicamenteux adjuvant (), Vaccins à ADN (administration et posologie), Vaccins à ADN (génétique).
- MESH :
- administration et posologie : Lévamisole, Vaccins à ADN.
- génétique : Activation des lymphocytes, Protéines nucléocapside, Syndrome respiratoire aigu sévère, Vaccins à ADN.
- immunologie : Activation des lymphocytes, Cytokines, Lymphocytes auxiliaires Th1, Protéines nucléocapside, Syndrome respiratoire aigu sévère.
- métabolisme : Adjuvants immunologiques.
- Activation des lymphocytes, Animaux, Femelle, Lymphocytes auxiliaires Th1, Souris, Souris de lignée BALB C, Syndrome respiratoire aigu sévère, Thérapie génétique, Traitement médicamenteux adjuvant.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (metabolism), Animals, Chemotherapy, Adjuvant (methods), Cytokines (immunology), Female, Genetic Therapy (methods), Levamisole (administration & dosage), Lymphocyte Activation (drug effects), Lymphocyte Activation (genetics), Lymphocyte Activation (immunology), Mice, Mice, Inbred BALB C, Nucleocapsid Proteins (genetics), Nucleocapsid Proteins (immunology), Severe Acute Respiratory Syndrome (genetics), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (prevention & control), Th1 Cells (drug effects), Th1 Cells (immunology), Vaccines, DNA (administration & dosage), Vaccines, DNA (genetics).
- MESH :
- chemical , administration & dosage : Levamisole, Vaccines, DNA.
- chemical , genetics : Nucleocapsid Proteins, Vaccines, DNA.
- chemical , immunology : Cytokines, Nucleocapsid Proteins.
- chemical , metabolism : Adjuvants, Immunologic.
- drug effects : Lymphocyte Activation, Th1 Cells.
- genetics : Lymphocyte Activation, Severe Acute Respiratory Syndrome.
- immunology : Lymphocyte Activation, Severe Acute Respiratory Syndrome, Th1 Cells.
- methods : Chemotherapy, Adjuvant, Genetic Therapy.
- prevention & control : Severe Acute Respiratory Syndrome.
- Animals, Female, Mice, Mice, Inbred BALB C.
Abstract
Vaccination against the SARS-CoV infection is an attractive means to control the spread of viruses in public. In this study, we employed a DNA vaccine technology with the levamisole, our newly discovered chemical adjuvant, to generate Th1 type of response. To avoid the enhancement antibody issue, genes encoding the nucleocapsid, membrane, and envelope protein of SARS-CoV were cloned and their expressions in mammalian cells were determined. After the intramuscular introduction into animals, we observed that the constructs of the E, M, and N genes could induce high levels of specific antibodies, T cell proliferations, IFN-gamma, DTH responses, and in vivo cytotoxic T cells activities specifically against SARS-CoV antigens. The highest immune responses were generated by the construct encoding the nucleocapsid protein. The results suggest that the N, M, and E genes could be used as the targets to prevent SARS-CoV infection in the DNA vaccine development.
DOI: 10.1016/j.bbrc.2005.01.048
PubMed: 15707974
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002891
Links to Exploration step
pubmed:15707974Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice.</title>
<author><name sortKey="Jin, Huali" sort="Jin, Huali" uniqKey="Jin H" first="Huali" last="Jin">Huali Jin</name>
<affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory for Agro-Biotechnology, College of Biological Science, China Agricultural University, Beijing 100094, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>State Key Laboratory for Agro-Biotechnology, College of Biological Science, China Agricultural University, Beijing 100094</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Xiao, Chong" sort="Xiao, Chong" uniqKey="Xiao C" first="Chong" last="Xiao">Chong Xiao</name>
</author>
<author><name sortKey="Chen, Ze" sort="Chen, Ze" uniqKey="Chen Z" first="Ze" last="Chen">Ze Chen</name>
</author>
<author><name sortKey="Kang, Youmin" sort="Kang, Youmin" uniqKey="Kang Y" first="Youmin" last="Kang">Youmin Kang</name>
</author>
<author><name sortKey="Ma, Yijie" sort="Ma, Yijie" uniqKey="Ma Y" first="Yijie" last="Ma">Yijie Ma</name>
</author>
<author><name sortKey="Zhu, Kaichun" sort="Zhu, Kaichun" uniqKey="Zhu K" first="Kaichun" last="Zhu">Kaichun Zhu</name>
</author>
<author><name sortKey="Xie, Qifa" sort="Xie, Qifa" uniqKey="Xie Q" first="Qifa" last="Xie">Qifa Xie</name>
</author>
<author><name sortKey="Tu, Yixian" sort="Tu, Yixian" uniqKey="Tu Y" first="Yixian" last="Tu">Yixian Tu</name>
</author>
<author><name sortKey="Yu, Yang" sort="Yu, Yang" uniqKey="Yu Y" first="Yang" last="Yu">Yang Yu</name>
</author>
<author><name sortKey="Wang, Bin" sort="Wang, Bin" uniqKey="Wang B" first="Bin" last="Wang">Bin Wang</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2005">2005</date>
<idno type="RBID">pubmed:15707974</idno>
<idno type="pmid">15707974</idno>
<idno type="doi">10.1016/j.bbrc.2005.01.048</idno>
<idno type="wicri:Area/PubMed/Corpus">002891</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002891</idno>
<idno type="wicri:Area/PubMed/Curation">002891</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002891</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice.</title>
<author><name sortKey="Jin, Huali" sort="Jin, Huali" uniqKey="Jin H" first="Huali" last="Jin">Huali Jin</name>
<affiliation wicri:level="1"><nlm:affiliation>State Key Laboratory for Agro-Biotechnology, College of Biological Science, China Agricultural University, Beijing 100094, China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>State Key Laboratory for Agro-Biotechnology, College of Biological Science, China Agricultural University, Beijing 100094</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Xiao, Chong" sort="Xiao, Chong" uniqKey="Xiao C" first="Chong" last="Xiao">Chong Xiao</name>
</author>
<author><name sortKey="Chen, Ze" sort="Chen, Ze" uniqKey="Chen Z" first="Ze" last="Chen">Ze Chen</name>
</author>
<author><name sortKey="Kang, Youmin" sort="Kang, Youmin" uniqKey="Kang Y" first="Youmin" last="Kang">Youmin Kang</name>
</author>
<author><name sortKey="Ma, Yijie" sort="Ma, Yijie" uniqKey="Ma Y" first="Yijie" last="Ma">Yijie Ma</name>
</author>
<author><name sortKey="Zhu, Kaichun" sort="Zhu, Kaichun" uniqKey="Zhu K" first="Kaichun" last="Zhu">Kaichun Zhu</name>
</author>
<author><name sortKey="Xie, Qifa" sort="Xie, Qifa" uniqKey="Xie Q" first="Qifa" last="Xie">Qifa Xie</name>
</author>
<author><name sortKey="Tu, Yixian" sort="Tu, Yixian" uniqKey="Tu Y" first="Yixian" last="Tu">Yixian Tu</name>
</author>
<author><name sortKey="Yu, Yang" sort="Yu, Yang" uniqKey="Yu Y" first="Yang" last="Yu">Yang Yu</name>
</author>
<author><name sortKey="Wang, Bin" sort="Wang, Bin" uniqKey="Wang B" first="Bin" last="Wang">Bin Wang</name>
</author>
</analytic>
<series><title level="j">Biochemical and biophysical research communications</title>
<idno type="ISSN">0006-291X</idno>
<imprint><date when="2005" type="published">2005</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (metabolism)</term>
<term>Animals</term>
<term>Chemotherapy, Adjuvant (methods)</term>
<term>Cytokines (immunology)</term>
<term>Female</term>
<term>Genetic Therapy (methods)</term>
<term>Levamisole (administration & dosage)</term>
<term>Lymphocyte Activation (drug effects)</term>
<term>Lymphocyte Activation (genetics)</term>
<term>Lymphocyte Activation (immunology)</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
<term>Nucleocapsid Proteins (genetics)</term>
<term>Nucleocapsid Proteins (immunology)</term>
<term>Severe Acute Respiratory Syndrome (genetics)</term>
<term>Severe Acute Respiratory Syndrome (immunology)</term>
<term>Severe Acute Respiratory Syndrome (prevention & control)</term>
<term>Th1 Cells (drug effects)</term>
<term>Th1 Cells (immunology)</term>
<term>Vaccines, DNA (administration & dosage)</term>
<term>Vaccines, DNA (genetics)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Activation des lymphocytes ()</term>
<term>Activation des lymphocytes (génétique)</term>
<term>Activation des lymphocytes (immunologie)</term>
<term>Adjuvants immunologiques (métabolisme)</term>
<term>Animaux</term>
<term>Cytokines (immunologie)</term>
<term>Femelle</term>
<term>Lymphocytes auxiliaires Th1 ()</term>
<term>Lymphocytes auxiliaires Th1 (immunologie)</term>
<term>Lévamisole (administration et posologie)</term>
<term>Protéines nucléocapside (génétique)</term>
<term>Protéines nucléocapside (immunologie)</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Syndrome respiratoire aigu sévère ()</term>
<term>Syndrome respiratoire aigu sévère (génétique)</term>
<term>Syndrome respiratoire aigu sévère (immunologie)</term>
<term>Thérapie génétique ()</term>
<term>Traitement médicamenteux adjuvant ()</term>
<term>Vaccins à ADN (administration et posologie)</term>
<term>Vaccins à ADN (génétique)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Levamisole</term>
<term>Vaccines, DNA</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Nucleocapsid Proteins</term>
<term>Vaccines, DNA</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Cytokines</term>
<term>Nucleocapsid Proteins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Adjuvants, Immunologic</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Lévamisole</term>
<term>Vaccins à ADN</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Lymphocyte Activation</term>
<term>Th1 Cells</term>
</keywords>
<keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>Lymphocyte Activation</term>
<term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Activation des lymphocytes</term>
<term>Protéines nucléocapside</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Vaccins à ADN</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Activation des lymphocytes</term>
<term>Cytokines</term>
<term>Lymphocytes auxiliaires Th1</term>
<term>Protéines nucléocapside</term>
<term>Syndrome respiratoire aigu sévère</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Lymphocyte Activation</term>
<term>Severe Acute Respiratory Syndrome</term>
<term>Th1 Cells</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Chemotherapy, Adjuvant</term>
<term>Genetic Therapy</term>
</keywords>
<keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Adjuvants immunologiques</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Female</term>
<term>Mice</term>
<term>Mice, Inbred BALB C</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Activation des lymphocytes</term>
<term>Animaux</term>
<term>Femelle</term>
<term>Lymphocytes auxiliaires Th1</term>
<term>Souris</term>
<term>Souris de lignée BALB C</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Thérapie génétique</term>
<term>Traitement médicamenteux adjuvant</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Vaccination against the SARS-CoV infection is an attractive means to control the spread of viruses in public. In this study, we employed a DNA vaccine technology with the levamisole, our newly discovered chemical adjuvant, to generate Th1 type of response. To avoid the enhancement antibody issue, genes encoding the nucleocapsid, membrane, and envelope protein of SARS-CoV were cloned and their expressions in mammalian cells were determined. After the intramuscular introduction into animals, we observed that the constructs of the E, M, and N genes could induce high levels of specific antibodies, T cell proliferations, IFN-gamma, DTH responses, and in vivo cytotoxic T cells activities specifically against SARS-CoV antigens. The highest immune responses were generated by the construct encoding the nucleocapsid protein. The results suggest that the N, M, and E genes could be used as the targets to prevent SARS-CoV infection in the DNA vaccine development.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15707974</PMID>
<DateCompleted><Year>2005</Year>
<Month>04</Month>
<Day>08</Day>
</DateCompleted>
<DateRevised><Year>2020</Year>
<Month>03</Month>
<Day>26</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-291X</ISSN>
<JournalIssue CitedMedium="Print"><Volume>328</Volume>
<Issue>4</Issue>
<PubDate><Year>2005</Year>
<Month>Mar</Month>
<Day>25</Day>
</PubDate>
</JournalIssue>
<Title>Biochemical and biophysical research communications</Title>
<ISOAbbreviation>Biochem. Biophys. Res. Commun.</ISOAbbreviation>
</Journal>
<ArticleTitle>Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice.</ArticleTitle>
<Pagination><MedlinePgn>979-86</MedlinePgn>
</Pagination>
<Abstract><AbstractText>Vaccination against the SARS-CoV infection is an attractive means to control the spread of viruses in public. In this study, we employed a DNA vaccine technology with the levamisole, our newly discovered chemical adjuvant, to generate Th1 type of response. To avoid the enhancement antibody issue, genes encoding the nucleocapsid, membrane, and envelope protein of SARS-CoV were cloned and their expressions in mammalian cells were determined. After the intramuscular introduction into animals, we observed that the constructs of the E, M, and N genes could induce high levels of specific antibodies, T cell proliferations, IFN-gamma, DTH responses, and in vivo cytotoxic T cells activities specifically against SARS-CoV antigens. The highest immune responses were generated by the construct encoding the nucleocapsid protein. The results suggest that the N, M, and E genes could be used as the targets to prevent SARS-CoV infection in the DNA vaccine development.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jin</LastName>
<ForeName>Huali</ForeName>
<Initials>H</Initials>
<AffiliationInfo><Affiliation>State Key Laboratory for Agro-Biotechnology, College of Biological Science, China Agricultural University, Beijing 100094, China.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Xiao</LastName>
<ForeName>Chong</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y"><LastName>Chen</LastName>
<ForeName>Ze</ForeName>
<Initials>Z</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kang</LastName>
<ForeName>Youmin</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Ma</LastName>
<ForeName>Yijie</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Zhu</LastName>
<ForeName>Kaichun</ForeName>
<Initials>K</Initials>
</Author>
<Author ValidYN="Y"><LastName>Xie</LastName>
<ForeName>Qifa</ForeName>
<Initials>Q</Initials>
</Author>
<Author ValidYN="Y"><LastName>Tu</LastName>
<ForeName>Yixian</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Yu</LastName>
<ForeName>Yang</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y"><LastName>Wang</LastName>
<ForeName>Bin</ForeName>
<Initials>B</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Biochem Biophys Res Commun</MedlineTA>
<NlmUniqueID>0372516</NlmUniqueID>
<ISSNLinking>0006-291X</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019590">Nucleocapsid Proteins</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D019444">Vaccines, DNA</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>2880D3468G</RegistryNumber>
<NameOfSubstance UI="D007978">Levamisole</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015316" MajorTopicYN="N">Genetic Therapy</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007978" MajorTopicYN="N">Levamisole</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008213" MajorTopicYN="N">Lymphocyte Activation</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019590" MajorTopicYN="N">Nucleocapsid Proteins</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018417" MajorTopicYN="N">Th1 Cells</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D019444" MajorTopicYN="N">Vaccines, DNA</DescriptorName>
<QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName>
<QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year>
<Month>01</Month>
<Day>08</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2005</Year>
<Month>2</Month>
<Day>15</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>4</Month>
<Day>9</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2005</Year>
<Month>2</Month>
<Day>15</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15707974</ArticleId>
<ArticleId IdType="pii">S0006-291X(05)00102-6</ArticleId>
<ArticleId IdType="doi">10.1016/j.bbrc.2005.01.048</ArticleId>
<ArticleId IdType="pmc">PMC7092846</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Immunol. 2000 Oct 15;165(8):4748-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11035120</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Annu Rev Immunol. 2000;18:927-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10837079</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Gen Virol. 1999 Oct;80 ( Pt 10):2559-2564</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10573147</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 1998 Nov 15;161(10):5338-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9820507</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Gen Virol. 2002 Jan;83(Pt 1):1-10</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11752695</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Blood. 2002 Aug 15;100(4):1153-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12149191</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1988 Jan;62(1):8-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2824858</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 2000 Jun 1;164(11):5905-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10820272</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Comp Immunol Microbiol Infect Dis. 1981;4(2):175-89</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6754243</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2002 May;76(9):4222-32</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11932387</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 2004 Jul 29;22(21-22):2925-35</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15246629</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Virus Res. 1999 Dec 1;65(1):75-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10564754</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1990 Mar;64(3):1407-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">2154621</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2004 May;78(9):4638-45</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15078946</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 2001 Jan 15;166(2):1405-13</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11145726</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol. 2002 Jan 15;168(2):834-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11777979</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 1994 Dec;12(16):1495-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">7879412</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1999 Jul;73(7):5301-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10364276</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2001 Mar;75(6):2660-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11222689</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 2001 Oct;75(19):9037-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11533167</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Virol. 1992 Feb;66(2):743-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">1309909</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Infect Immun. 2001 Feb;69(2):681-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11159955</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Vaccine. 1999 Feb 26;17(7-8):653-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10067670</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Immunol Lett. 2004 Apr 15;92(3):237-43</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15081618</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Science. 1993 Mar 19;259(5102):1745-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8456302</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Gen Virol. 2003 Aug;84(Pt 8):2237-2244</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12867656</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Immunol Methods. 1993 Sep 27;165(1):37-46</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8409467</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Exp Biol. 2003 Nov;206(Pt 21):3771-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14506212</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Infect Immun. 2001 Feb;69(2):1202-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11160023</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Semin Immunol. 1997 Oct;9(5):271-83</Citation>
<ArticleIdList><ArticleId IdType="pubmed">9327522</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002891 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 002891 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:15707974 |texte= Induction of Th1 type response by DNA vaccinations with N, M, and E genes against SARS-CoV in mice. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:15707974" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
This area was generated with Dilib version V0.6.33. |